Locations

Locations

Locations

North America, including USA and Canada
Western and Eastern Europe
Middle East and MENA Countries
India, Malaysia, Singapore
Australia and New Zealand
Asia and Pacific Rim, including Japan, Korea and China
Latin America

US Corporate Office

The Sage Group Inc.
24 E. Main Street, Box 5365
Clinton, New Jersey 08809   USA
Attn: Wayne Pambianchi

Tel: +1 908 230 6170
wayne@sagehealthcare.com

EU Corporate Office

Sage Healthcare Ltd.
The Stockyard
Creake Road, Syderstone, King's Lynn  PE31 8SG  UK
Attn: Dr. Bill Mason

Phone: +44 7785 950134
wtm@sagehealthcare.com

Sage APAC

The Sage Group has a strong base in Australia, New Zealand and APAC, led by experienced partner Chris Rossidis.

Sage has worked with numerous pharma and biotech companies in the Antipodes, including both leading companies and financial organisations. Australia and NZ are vibrant communities for globally respected organisations in the industry and as well this area boasts a strong clinical community hosting numerous trials for companies worldwide.

​For more information about Sage and opportunities for collaboration with our Australia/NZ services, please visit our website, contact:​

APAC Corporate Office

Chris Rossidis

Sage Australia

Suite 3, Level 1, 2 Theatre Place
Canterbury VIC 3126 Australia
Phone: +61 (417) 112 590

crossidis@sagehealthcare.com

Sage China 賢者中國

The Sage Group, Inc. offers a full service for Chinese companies wishing to partner their assets in the Rest of World, especially USA and Europe, and for Western companies wishing to partner their assets with the rich corporate pharma community in the People’s Republic of China. The principal objective is to broaden Sage's strategic licensing, M&A and partnering capabilities for our healthcare clients in pharmaceuticals, biopharmaceuticals, biotechnology, diagnostics and medical technology. This builds upon Sage’s 30+ years of  experience in such transactions.
​

​​Sage offers clients a full strategic advisory service with our team in China including:

Assisting our Chinese client companies with out-licensing their assets into global markets with a focus on North America and Europe

Assisting our clients in the West with licensing their pharma, diagnostic and medtech assets into the dynamic healthcare market in the Republic of China

This initiative follows on from increasing demand from our Western and Chinese clients for assistance in conducting cross-border strategic transaction initiatives to assist them in licensing and divesting their assets, and also our clients seeking new assets for in-licensing into North America, Europe and China.​

Sage has conducted successfully a range of transactions with both Western and Chinese clients. One recent deal with an infectious disease asset for our Chinese client realised a very significant transaction with GSK, a top 10 global pharma company.​

For a confidential discussion in more detail, please emails us SageGroupChina@sagehealthcare.com.

The Sage Group, Inc. offers a full service for Chinese companies wishing to partner their assets in the Rest of World, especially USA and Europe, and for Western companies wishing to partner their assets with the rich corporate pharma community in the People’s Republic of China. The principal objective is to broaden Sage's strategic licensing, M&A and partnering capabilities for our healthcare clients in pharmaceuticals, biopharmaceuticals, biotechnology, diagnostics and medical technology. This builds upon Sage’s 30+ years of  experience in such transactions.
​

​​Sage offers clients a full strategic advisory service with our team in China including:

Assisting our Chinese client companies with out-licensing their assets into global markets with a focus on North America and Europe

Assisting our clients in the West with licensing their pharma, diagnostic and medtech assets into the dynamic healthcare market in the Republic of China

This initiative follows on from increasing demand from our Western and Chinese clients for assistance in conducting cross-border strategic transaction initiatives to assist them in licensing and divesting their assets, and also our clients seeking new assets for in-licensing into North America, Europe and China.​

Sage has conducted successfully a range of transactions with both Western and Chinese clients. One recent deal with an infectious disease asset for our Chinese client realised a very significant transaction with GSK, a top 10 global pharma company.​

For a confidential discussion in more detail, please emails us SageGroupChina@sagehealthcare.com.

The Sage Group, Inc. offers a full service for Chinese companies wishing to partner their assets in the Rest of World, especially USA and Europe, and for Western companies wishing to partner their assets with the rich corporate pharma community in the People’s Republic of China. The principal objective is to broaden Sage's strategic licensing, M&A and partnering capabilities for our healthcare clients in pharmaceuticals, biopharmaceuticals, biotechnology, diagnostics and medical technology. This builds upon Sage’s 30+ years of  experience in such transactions.
​

​​Sage offers clients a full strategic advisory service with our team in China including:

Assisting our Chinese client companies with out-licensing their assets into global markets with a focus on North America and Europe

Assisting our clients in the West with licensing their pharma, diagnostic and medtech assets into the dynamic healthcare market in the Republic of China

This initiative follows on from increasing demand from our Western and Chinese clients for assistance in conducting cross-border strategic transaction initiatives to assist them in licensing and divesting their assets, and also our clients seeking new assets for in-licensing into North America, Europe and China.​

Sage has conducted successfully a range of transactions with both Western and Chinese clients. One recent deal with an infectious disease asset for our Chinese client realised a very significant transaction with GSK, a top 10 global pharma company.​

For a confidential discussion in more detail, please emails us SageGroupChina@sagehealthcare.com.

Sage Japan 日本と言う

Sage has global reach into Japan, Korea and APAC Sage can support strategic licensing, M&A and partnering capabilities for our healthcare clients in pharmaceuticals, biopharmaceuticals, biotechnology, diagnostics and medical technology. This builds upon Sage’s 30years of  experience in such transactions.

Sage works closely with our esteemed partner e-Projection in Tokyo, a bioscience consulting firm which can offer a range of services for strategic market assessment, licensing and partnering with Japanese companies. More detail can be found here!
​

The Sage Group now offers clients a full strategic advisory service including:

Assisting our clients in the West with licensing their pharma, diagnostic and medtech assets into the dynamic healthcare market in the Japan

Assisting Japanese companies with out-licensing their assets into global markets with a focus on North America and Europe

​

For a confidential discussion in more detail, please email us at Corporate@sagehealthcare.com.

Sage has global reach into Japan, Korea and APAC Sage can support strategic licensing, M&A and partnering capabilities for our healthcare clients in pharmaceuticals, biopharmaceuticals, biotechnology, diagnostics and medical technology. This builds upon Sage’s 30years of  experience in such transactions.

Sage works closely with our esteemed partner e-Projection in Tokyo, a bioscience consulting firm which can offer a range of services for strategic market assessment, licensing and partnering with Japanese companies. More detail can be found here!
​

The Sage Group now offers clients a full strategic advisory service including:

Assisting our clients in the West with licensing their pharma, diagnostic and medtech assets into the dynamic healthcare market in the Japan

Assisting Japanese companies with out-licensing their assets into global markets with a focus on North America and Europe

​

For a confidential discussion in more detail, please email us at Corporate@sagehealthcare.com.

Sage has global reach into Japan, Korea and APAC Sage can support strategic licensing, M&A and partnering capabilities for our healthcare clients in pharmaceuticals, biopharmaceuticals, biotechnology, diagnostics and medical technology. This builds upon Sage’s 30years of  experience in such transactions.

Sage works closely with our esteemed partner e-Projection in Tokyo, a bioscience consulting firm which can offer a range of services for strategic market assessment, licensing and partnering with Japanese companies. More detail can be found here!
​

The Sage Group now offers clients a full strategic advisory service including:

Assisting our clients in the West with licensing their pharma, diagnostic and medtech assets into the dynamic healthcare market in the Japan

Assisting Japanese companies with out-licensing their assets into global markets with a focus on North America and Europe

​

For a confidential discussion in more detail, please email us at Corporate@sagehealthcare.com.

Sage India

Sage has partnered with Renuto Consulting in New Delhi to offer its clients unparalleled expertise for addressing the large Indian pharmaceutical, medical device and diagnostics market.

Led by Reena Bhattacharya of Renuto Consulting, both pharmaceutical professionals by education and working experience, Sage's strategic partners have over five decades of cumulative experience in management of transactions with Indian-based pharmaceutical companies to arrive at feasible business solutions for ease of decision making. We offer​

Extensive hands-on knowledge for establishing business in India

Business network of real time working professionals in related fields for quick contacts 

Years of partnering acumen and goodwill with reputed companies in India 

Deep knowledge of regulations in India for ease of registration of your products 

Rational contract drafting and negotiation skills for creating win-win situation 

Market research and data analysis for decision making 

Business turn around; revival of brands and success mantras

 

Our strategic partner, Reena Bhattacharya, facilitates international companies to explore Indian pharmaceutical, nutraceuticals, OTC, medical devices and diagnostics markets

 

We offer a host of professional services in various domains in pharmaceutical & healthcare segments & help corporate growth and development. These services include:

Business development, licensing & partnering

Negotiations & contracts

Project valuation

Market estimation & research

Marketing & brand management

Commercialization assistance

 

The Sage Group strategic partner in India:

Renuto Consulting
B1 / 632, Second Floor
Janakpuri (East)
New Delhi – 110058
INDIA

Mobile: +91 98181 95454
Email: info@renuto.com
Website: https://www.renuto.com 

Principal Biographies

Reena Bhattacharya

Reena Bhattacharya is the founder & strategy consultant at Renuto Consulting, based in New Delhi, India.  She offers pharmaceutical & healthcare consulting in the areas of licensing, brand management, market estimation and 360 degree partnering. She has over two decades of experience in the Indian pharmaceutical industry, including in-licensing & marketing internationally recognized therapies from European and US based companies in the Indian market. Reena is an astute marketer & strategist who understands market needs, identifies gaps & offers products that expand the portfolios of companies. She also has deep domain knowledge about IP (patents & regulations), OTC markets and market research. 

Her strengths include following a scientific approach to identify partnering opportunities that meet the needs of both the partners & creating win-win solutions. She understands companies, including their product partnering, market and commercial needs.  Her partnering deliberations not only create synergistic solutions but also create long-term relationships between companies. 

Sage has partnered with Renuto Consulting in New Delhi to offer its clients unparalleled expertise for addressing the large Indian pharmaceutical, medical device and diagnostics market.

Led by Reena Bhattacharya of Renuto Consulting, both pharmaceutical professionals by education and working experience, Sage's strategic partners have over five decades of cumulative experience in management of transactions with Indian-based pharmaceutical companies to arrive at feasible business solutions for ease of decision making. We offer​

Extensive hands-on knowledge for establishing business in India

Business network of real time working professionals in related fields for quick contacts 

Years of partnering acumen and goodwill with reputed companies in India 

Deep knowledge of regulations in India for ease of registration of your products 

Rational contract drafting and negotiation skills for creating win-win situation 

Market research and data analysis for decision making 

Business turn around; revival of brands and success mantras

 

Our strategic partner, Reena Bhattacharya, facilitates international companies to explore Indian pharmaceutical, nutraceuticals, OTC, medical devices and diagnostics markets

 

We offer a host of professional services in various domains in pharmaceutical & healthcare segments & help corporate growth and development. These services include:

Business development, licensing & partnering

Negotiations & contracts

Project valuation

Market estimation & research

Marketing & brand management

Commercialization assistance

 

The Sage Group strategic partner in India:

Renuto Consulting
B1 / 632, Second Floor
Janakpuri (East)
New Delhi – 110058
INDIA

Mobile: +91 98181 95454
Email: info@renuto.com
Website: https://www.renuto.com 

Principal Biographies

Reena Bhattacharya

Reena Bhattacharya is the founder & strategy consultant at Renuto Consulting, based in New Delhi, India.  She offers pharmaceutical & healthcare consulting in the areas of licensing, brand management, market estimation and 360 degree partnering. She has over two decades of experience in the Indian pharmaceutical industry, including in-licensing & marketing internationally recognized therapies from European and US based companies in the Indian market. Reena is an astute marketer & strategist who understands market needs, identifies gaps & offers products that expand the portfolios of companies. She also has deep domain knowledge about IP (patents & regulations), OTC markets and market research. 

Her strengths include following a scientific approach to identify partnering opportunities that meet the needs of both the partners & creating win-win solutions. She understands companies, including their product partnering, market and commercial needs.  Her partnering deliberations not only create synergistic solutions but also create long-term relationships between companies. 

Sage has partnered with Renuto Consulting in New Delhi to offer its clients unparalleled expertise for addressing the large Indian pharmaceutical, medical device and diagnostics market.

Led by Reena Bhattacharya of Renuto Consulting, both pharmaceutical professionals by education and working experience, Sage's strategic partners have over five decades of cumulative experience in management of transactions with Indian-based pharmaceutical companies to arrive at feasible business solutions for ease of decision making. We offer​

Extensive hands-on knowledge for establishing business in India

Business network of real time working professionals in related fields for quick contacts 

Years of partnering acumen and goodwill with reputed companies in India 

Deep knowledge of regulations in India for ease of registration of your products 

Rational contract drafting and negotiation skills for creating win-win situation 

Market research and data analysis for decision making 

Business turn around; revival of brands and success mantras

 

Our strategic partner, Reena Bhattacharya, facilitates international companies to explore Indian pharmaceutical, nutraceuticals, OTC, medical devices and diagnostics markets

 

We offer a host of professional services in various domains in pharmaceutical & healthcare segments & help corporate growth and development. These services include:

Business development, licensing & partnering

Negotiations & contracts

Project valuation

Market estimation & research

Marketing & brand management

Commercialization assistance

 

The Sage Group strategic partner in India:

Renuto Consulting
B1 / 632, Second Floor
Janakpuri (East)
New Delhi – 110058
INDIA

Mobile: +91 98181 95454
Email: info@renuto.com
Website: https://www.renuto.com 

Principal Biographies

Reena Bhattacharya

Reena Bhattacharya is the founder & strategy consultant at Renuto Consulting, based in New Delhi, India.  She offers pharmaceutical & healthcare consulting in the areas of licensing, brand management, market estimation and 360 degree partnering. She has over two decades of experience in the Indian pharmaceutical industry, including in-licensing & marketing internationally recognized therapies from European and US based companies in the Indian market. Reena is an astute marketer & strategist who understands market needs, identifies gaps & offers products that expand the portfolios of companies. She also has deep domain knowledge about IP (patents & regulations), OTC markets and market research. 

Her strengths include following a scientific approach to identify partnering opportunities that meet the needs of both the partners & creating win-win solutions. She understands companies, including their product partnering, market and commercial needs.  Her partnering deliberations not only create synergistic solutions but also create long-term relationships between companies. 

Sage Clients Past and Present

3i
3-D Pharma
ABM Therapeutics
Acaris
Accro Bioscience
Acolyte Biomedica
Alfacell
Alita
Amarin
American Biogenetic Sciences
AndCare
Anergen
​Applied Pharmaceutical Research (APR)
Asit Biotech
Atrix
Aurogen
Auson Pharma
AustinPx
Aventis
AzuRx Biopharma
BC&D Concepts
B. Braun
Baxter
Bayer Innovation
Berkley Heart Labs
BioCancell
BioCryst
BioNature
BioPharm Solutions
Biotrin
Biouniversa
BMD
BMT
Brahms
Brenner Securities
Bristol-Myers Squibb
Bullfrog AI
Cadrenal
Cambridge Molecular Diag Cambridge University
Camstent
Canbex Therapeutics
Cancer Prevention Pharmaceuticals
Carr Separations
Carter Wallace
Celgene
Cenix
Centeon
​Chordate Medical
Chromagen
CLI Oncology
Closure Medical
Coagulant Therapeutics
Coller Capital
Combinature
Conceptomed
Connaught
CNSystems
Coerleus
Cranfield Univ
Cytocell
Cytomyx
CytosinLab
Daewoong
Data2Life
​Delcath Medical
Devco
DFJ Esprit
Discovery Labs
Dompe Pharmaceuticals
Drug Royalty
Dura
e2V Technologies
Echo Pharmaceuticals
Emisphere
Enkam
Enzon
EpiAxis Therapeutics
Escend Therapeutics
Exhalation Technology
Evecxia
Exonhit (now Diaxonhit)
FabreKramer Pharmaceuticals
Federal Trade Commission (Trustee)
Fluxome
Focal, Inc.
Gamma-A
GEM Pharmaceuticals
GeneBio
GenesysDx
Giltech
Glyko
Gresmex
Guanghzou Doublle Therapeutics
Gynetics
Haemacure
Harbourvest
Harvard University
Hatchtech
HCP
Help Therapeutics
Hemispherx
Huahui Health
Hycor
IGF Oncology
Imaginot
Immunobiology Ltd
Immune Response Corp.
Immunomedics
Intellomx
IPSO Ventures
IP2IPO
IRM
Isofol
i-STAT
Itrom
Jantar
JJDC

Joint Polish Investment Fund
Keystone Nano
Kinnov Therapeutics
KPL
La Jolla Pharmaceuticals
Lifecodes
Life Science Resources
Luminex
Luzitin
Madeleine Therapeutics
​Mateon Therapeutics
McKinley
MEC
medac GmbH
MedCenter Inc
Medical Science Partners
MediGlobe
Merakris
Metabolomic Diagnostics
MMC Ventures
Microprevention Tests
MIT
Mountain View Pharma
Natimmune
Neuromedica
Nicox
Nitromed
Nitto Denko
NJ Economic Dev Auth
Norchip
Notogen
Nova Molecular
Noven
Odyssey Therapeutics
Omega
OncoSec
Opticul
Optimata
Orthomimetics
Palau Pharmaceuticals
PaxMedica
Pennsylvania State Univ.
Pentech
Phairson Ltd
Pharmaply
Pheromone Sciences
Pipex
Pivotal
Pluristem
PneumaCare
Polypid
Precious Cells Group
Proimmune
Prolong Pharmaceuticals
Quest Products
Ranier Technology
Redhill Biopharma
Regenerys
Relmada
Research Corporation Technology (RCT)
Respira Therapeutics
Response Biomedical
RGene Therapeutics
Rohm & Haas
SAJE Therapeutics
Samyang
Scienion
Sense Proteomic
Serpin Pharma
SK Corporation
Small Molecule Therapeutics
Societe General
Solasia
​Solvotrin
Soros Fund Management
Southcoast Capital
Sphere Medical
Spherium Biomed
Squarex
Starmab Biomed
Starrygene
Supratek
Surgicon
​Syndrome X
Tanabe Seiyaku
Tandem
Tardimed
Targeted Genetics
TD2
Team Consulting
Teijin
TeraView
Teva
Thermo BioStar
Toolgen
Toray-Fuji Bionics
Transgenic Products
Transmolecular
Trinity Biotech
TwoBull Meditherapy
U.S. Biomaterials
Ultrafem
Univ. Cambridge/MIT
ValiRx
Veritas
Vesselon
Vestar
Visiox
Visus
Watson Phamaceuticals
WelGene
Wnt Research
Xing Technologies
Zeneca
Zeus
Zhimeng Biopharma
Zumutor

Join the sage mailing list

pages

Home

Home

About

About

Services

Services

Case Studies

Case Studies

Pricing

Pricing

Contact

Contact

© 2026 Sage Healthcare. All rights reserved.
UK Co. Reg No. 03118026

Site by Reson8

Site by Reson8

Join the sage mailing list

pages

Home

Home

About

About

Services

Services

Case Studies

Case Studies

Pricing

Pricing

Contact

Contact

© 2026 Sage Healthcare. All rights reserved.
UK Co. Reg No. 03118026

Site by Reson8

Site by Reson8

Join the sage mailing list

pages

Home

Home

About

About

Services

Services

Case Studies

Case Studies

Pricing

Pricing

Contact

Contact

© 2026. All rights reserved.

Site by Reson8

Site by Reson8